Logo image of INCR

INTERCURE LTD (INCR) Stock Fundamental Analysis

NASDAQ:INCR - Nasdaq - IL0011063760 - Common Stock - Currency: USD

1.64  0 (-0.1%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to INCR. INCR was compared to 194 industry peers in the Pharmaceuticals industry. INCR may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, INCR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

INCR had negative earnings in the past year.
In the past year INCR has reported a negative cash flow from operations.
In multiple years INCR reported negative net income over the last 5 years.
In multiple years INCR reported negative operating cash flow during the last 5 years.
INCR Yearly Net Income VS EBIT VS OCF VS FCFINCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

INCR has a Return On Assets of -7.88%. This is in the better half of the industry: INCR outperforms 73.51% of its industry peers.
INCR has a better Return On Equity (-13.61%) than 74.05% of its industry peers.
Looking at the Return On Invested Capital, with a value of 4.83%, INCR belongs to the top of the industry, outperforming 81.08% of the companies in the same industry.
Industry RankSector Rank
ROA -7.88%
ROE -13.61%
ROIC 4.83%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INCR Yearly ROA, ROE, ROICINCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20 -40 -60

1.3 Margins

Looking at the Operating Margin, with a value of 9.64%, INCR belongs to the top of the industry, outperforming 81.62% of the companies in the same industry.
INCR has a Gross Margin (30.47%) which is in line with its industry peers.
In the last couple of years the Gross Margin of INCR has declined.
Industry RankSector Rank
OM 9.64%
PM (TTM) N/A
GM 30.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.28%
GM growth 5YN/A
INCR Yearly Profit, Operating, Gross MarginsINCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 -60

More info and screens

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so INCR is destroying value.
INCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INCR Yearly Shares OutstandingINCR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M
INCR Yearly Total Debt VS Total AssetsINCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M

2.2 Solvency

INCR has an Altman-Z score of 1.05. This is a bad value and indicates that INCR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.05, INCR is in line with its industry, outperforming 60.00% of the companies in the same industry.
A Debt/Equity ratio of 0.23 indicates that INCR is not too dependend on debt financing.
INCR has a Debt to Equity ratio (0.23) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z 1.05
ROIC/WACC0.47
WACC10.33%
INCR Yearly LT Debt VS Equity VS FCFINCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M 500M

2.3 Liquidity

INCR has a Current Ratio of 1.85. This is a normal value and indicates that INCR is financially healthy and should not expect problems in meeting its short term obligations.
INCR has a worse Current ratio (1.85) than 62.16% of its industry peers.
INCR has a Quick Ratio of 1.39. This is a normal value and indicates that INCR is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.39, INCR is doing worse than 69.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.39
INCR Yearly Current Assets VS Current LiabilitesINCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

INCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -237.58%.
Looking at the last year, INCR shows a decrease in Revenue. The Revenue has decreased by -8.52% in the last year.
Measured over the past years, INCR shows a very strong growth in Revenue. The Revenue has been growing by 76.16% on average per year.
EPS 1Y (TTM)-237.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-821.9%
Revenue 1Y (TTM)-8.52%
Revenue growth 3Y76.16%
Revenue growth 5YN/A
Sales Q2Q%236.68%

3.2 Future

The Earnings Per Share is expected to grow by 80.53% on average over the next years. This is a very strong growth
INCR is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.31% yearly.
EPS Next Y90.7%
EPS Next 2Y83%
EPS Next 3Y80.53%
EPS Next 5YN/A
Revenue Next Year-24.35%
Revenue Next 2Y2.66%
Revenue Next 3Y14.31%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
INCR Yearly Revenue VS EstimatesINCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M 500M
INCR Yearly EPS VS EstimatesINCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

INCR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INCR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INCR Price Earnings VS Forward Price EarningsINCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, INCR is valued cheaper than 89.73% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.68
INCR Per share dataINCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

INCR's earnings are expected to grow with 80.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y83%
EPS Next 3Y80.53%

More info and screens

0

5. Dividend

5.1 Amount

INCR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTERCURE LTD

NASDAQ:INCR (2/21/2025, 8:00:01 PM)

1.64

0 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2024-08-12/amc
Earnings (Next)N/A N/A
Inst Owners10.95%
Inst Owner Change-20.74%
Ins Owners38.42%
Ins Owner Change0%
Market Cap77.34M
Analysts82.86
Price TargetN/A
Short Float %0.14%
Short Ratio1.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.77
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 1.18
EV/EBITDA 7.68
EPS(TTM)-0.38
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.32
OCFYN/A
SpS2.12
BVpS2.71
TBVpS1.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.88%
ROE -13.61%
ROCE 6.11%
ROIC 4.83%
ROICexc 5.9%
ROICexgc 11.37%
OM 9.64%
PM (TTM) N/A
GM 30.47%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.28%
GM growth 5YN/A
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA 2.17
Cap/Depr 19.89%
Cap/Sales 0.74%
Interest Coverage 1.64
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.39
Altman-Z 1.05
F-Score3
WACC10.33%
ROIC/WACC0.47
Cap/Depr(3y)126.13%
Cap/Depr(5y)882.8%
Cap/Sales(3y)4.07%
Cap/Sales(5y)71.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-237.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-821.9%
EPS Next Y90.7%
EPS Next 2Y83%
EPS Next 3Y80.53%
EPS Next 5YN/A
Revenue 1Y (TTM)-8.52%
Revenue growth 3Y76.16%
Revenue growth 5YN/A
Sales Q2Q%236.68%
Revenue Next Year-24.35%
Revenue Next 2Y2.66%
Revenue Next 3Y14.31%
Revenue Next 5YN/A
EBIT growth 1Y-45.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year782.79%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-278.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-204.61%
OCF growth 3YN/A
OCF growth 5YN/A